CompletedPhase 2

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

United States135 participantsStarted 2007-02-27

Plain-language summary

The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males and/or Females of non-childbearing potential between 18 and 70 years of age
✓. History of mild to moderate hypertension

Exclusion criteria

✕. Type 1 or 2 diabetes on prescribed medications
✕. Secondary, severe, or malignant hypertension
✕. History of a significant cardiovascular event within the last 12 months of enrollment

What they're measuring

Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28

Timeframe: From 08:00 to 16:00 hours on Baseline (Day 0, 1 day prior to first double-blind dose of study drug) and Day 28

Trial details

NCT IDNCT00422461

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-01-28

Results submitted2021-09-13

View on ClinicalTrials.gov More Hypertension trials